Shares of ResMed RMD were flat in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 16.53% year over year to $1.41, which beat the estimate of $1.26.
Revenue of $800,011,000 higher by 8.67% from the same period last year, which beat the estimate of $783,180,000.
Looking Ahead
ResMed hasn't issued any earnings guidance for the time being.
ResMed hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Jan 28, 2021
Time: 04:30 PM
Technicals
Company's 52-week high was at $224.43
52-week low: $108.85
Price action over last quarter: Up 12.50%
Company Profile
ResMed is one of the largest global respiratory medical devices companies, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns 65% of revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
